Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05618080 · ClinicalTrials.gov registry record
LGMD R1 Natural History Study
A clinical trial of Limb Girdle Muscular Dystrophy and LGMD2A, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 12
- Study locations
NCT05618080: Recruiting study of Limb Girdle Muscular Dystrophy and LGMD2A, sponsored by Virginia Commonwealth University.
NCT05618080 is a study of Limb Girdle Muscular Dystrophy and LGMD2A that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 100 participants, below the 223-participant average among 6 other Limb Girdle Muscular Dystrophy trials with a reported enrollment target (55% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05618080, a study of Limb Girdle Muscular Dystrophy and LGMD2A, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Primary Outcome
The North Star Assessment for Dysferlinopathy (NSAD) is a functional scale specifically designed to measure motor performance in individuals with LGMD. It consists of 29 items that are considered clinically relevant items from the North Star Ambulatory Assessment and the Motor Function Measure 20 with a maximum score of 54 and higher scores indicate higher functional abilities.
Conditions Studied
Study Locations (12)
Other
- Leiden University Medical Center - Leiden
- Newcastle University - Newcastle upon Tyne
California
- University of California, Irvine - Orange
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- University of Florida - Gainesville
Indiana
- The Community Health Clinic, Inc. - Shipshewana
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Minnesota
- University of Minnesota, Department of Neurology - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2028-08 |
What NCT05618080 shows while recruiting
NCT05618080 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 223-participant average among 6 other Limb Girdle Muscular Dystrophy trials with a reported enrollment target (55% lower).
The record links to 4 conditions, with Limb Girdle Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT05618080 lists 12 locations in 11 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05618080 about?
NCT05618080 is a clinical study titled "LGMD R1 Natural History Study". This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
What is the current status of trial NCT05618080?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-01-31. Estimated completion is 2028-08.
What conditions does trial NCT05618080 study?
This clinical trial studies the following conditions: Limb Girdle Muscular Dystrophy, LGMD2A, Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy Type R1.
Who is sponsoring clinical trial NCT05618080?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05618080 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Limb Girdle Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
RECRUITING · Phase 1
-
Molecular Analysis of Patients With Neuromuscular Disease
RECRUITING
-
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
ACTIVE NOT RECRUITING · Phase 1
-
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
ACTIVE NOT RECRUITING
-
Biomarker Development in LGMD2i
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI